PharmAthene v. Siga [Premium]

CONCLUDED

Trial
01/03/11 – 01/21/11

Summary

Post-trial oral arguments scheduled for April 29, 2011.

In this Pharmaceutical mergers and acquisition litgation proceeding, Plaintiff PharmAthene alleged Siga Technologies of breaching its obligations to negotiate in good faith a definitive license agreement in accordance with the terms of license agreement term sheet it signed for the development of a small pox drug with the plaintiff.

The plaintiff was represented by attorney Roger Crane. The defendant in this case, Siga Technologies was represented by attorneys Harold Weinberger.


For more information, visit the CVN News Blog.

Outcome

The court found that SGIA was liable for the breach of contractual obligations to negotiate a license agreement in good faith and promissory estoppel. Judgment was entered for an equitable payment stream or equitable lien on the profits or the other qualifying proceeds associated with commercial sale of ST-246 or products that were derived from it Also, PharmAthene was awarded one-third of its attorneysÂ’ fees, expert witness costs, and other costs.

Case Information
Attorneys
Witnesses
Plaintiff
Defense
Judge
Donald Parsons
Jurisdiction
Delaware Court Of Chancery
Court
New Castle County Courthouse
Case Number
2627-VCP
Industry
Pharmaceutical
Practice Area
Commercial Law, Mergers and Acquisitions, Pharmaceuticals
Plaintiff
PharmAthene, Inc.
Defense
Siga
Expert Witnesses
Lay Witnesses

Sessions

JAN
3
JAN
4
JAN
5
JAN
6
JAN
7
JAN
10
JAN
11
JAN
12
JAN
18
PM Session
Defense Witness(es)
2 Chapters
JAN
19
JAN
21

Recording Disclaimer: This proceeding was recorded in full except noted sections that were not recorded.

AudioCaseFiles

Exclusive audio opinions to enhance your law school experience

AudioCaseFiles

Essentials

The most important and informative moments of each trial

Essentials

Training Libraries

Trial Advocacy, Rules of Evidence and Appellate Advocacy

Training

  • Follow Us